New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
08:41 EDTANIPANI Pharmaceuticals fundamentals appear on track, says Roth Capital
After ANI's stock came under considerable pressure, Roth Capital spoke with the company's management and thinks the company's fundamentals remain on track. The firm believes that the company's revenue and EPS could beat expectations, and it reiterates a Buy rating on the stock.
News For ANIP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
08:31 EDTANIPANI Pharmaceuticals announces launch of Etodolac 300mg capsules
ANI Pharmaceuticals announced the launch of Etodolac 300mg oral capsules, indicated for use in the management of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and acute pain. The US market for Etodolac 300mg capsules totals $9M on a trailing 12 month basis, per IMS Health.
January 27, 2015
17:51 EDTANIPS&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices
Subscribe for More Information
17:24 EDTANIPANI Pharmaceuticals to replace Gentiva Health in S&P 600 as of 2/2 close
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use